Lineage Cell Therapeutics (AMEX: LCTX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.030 | -0.040 | -0.0100 | ||||
REV | 7.320M | 5.237M | -2.083M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Lineage Cell Therapeutics (AMEX: LCTX) through any online brokerage.
There are no as such competitors for Lineage Cell Therapeutics.
The latest price target for Lineage Cell Therapeutics (AMEX: LCTX) was reported by B. Riley Securities on Tuesday, June 14, 2022. The analyst firm set a price target for 4.00 expecting LCTX to rise to within 12 months (a possible 143.16% upside). 2 analyst firms have reported ratings in the last year.
The stock price for Lineage Cell Therapeutics (AMEX: LCTX) is $1.645 last updated July 6, 2022, 7:59 PM UTC.
There are no upcoming dividends for Lineage Cell Therapeutics.
Lineage Cell Therapeutics’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Lineage Cell Therapeutics.
Lineage Cell Therapeutics is in the Healthcare sector and Biotechnology industry. They are listed on the AMEX.